



Beta Cell Preservation Working Group

Meeting Minutes
January 6, 2026

Participants

Lauren Culbreth (TCH); Laura Jacobsen (UFL); Shideh Majidi (Children's National); Lydia Holly (Children's National); Naomi Fogel (Lurie Children's); Carla Demeterco-Berggren (Rady); Dan DeSalvo (TCH); Vana Raman (Utah); Rachel Mullin (OHSU); David Broome (U Michigan); Mary Pat Gallagher (Hassenfeld); Todd Alonso (BDC); Nicole Rioles, Trevon Wright, Claire Rainey (T1DX)

Agenda

1. Welcome and Introductions (5 minutes)
2. White Paper Update (10–15 minutes)
3. Commentary Update and Submission Status (5 minutes)
4. Discussion: Priorities and Next Steps (10–15 minutes)
5. Action Items and Assignments (5 minutes)

White Paper Discussion

- Normal white paper: 10-12 pages, technical white papers: up to 30 pages.
- This white paper is larger, and the speaker wants to consider its use, whether it needs to be broken apart or used differently.
- The hope is to use pieces for a future change package and one or two full articles.

White Paper Aim

- White paper is a blueprint to move forward.
- Labeling for stage 3 diabetes is expected to be accepted around April or May 2026.
- The white paper can be a shared resource used in practice before, during, and after labeling, providing clear workflow guidelines.

- White paper is a working and active document, not perfect, but represents the best current understanding.
- Change package: takes what has already been learned and applied in practice, including best practices and lessons learned.
- Articles can be created after the change package and at later times to share more experiences in practice.

White Paper Audience

- The goal is for the white paper to be actively on the website and accessible to others, so other clinicians can find it, use it, and share their learnings.
- The white paper should be externally accessible.
- It is important to provide collected resources to facilitate implementation in different places.
- Resources like workflows, templates, and screenshots of examples have been added, with the ability to add more overtime.
- Carla has worked on initial drafts of the executive summary, introduction, and a literature review.

White Paper Version 2.0

- White paper version 2.0 is available in the work group sections under the beta cell white paper folder.
- The link will be put in the chat.
- Carla's introduction and executive summary are included.
- All other sections have been incorporated.
- Claire created a bibliography as a separate document in the subfolder.
- The white paper is currently a 50-page document with all sections incorporated.

White Paper Review and Editing

- The current version is being finalized internally.
- A reminder link will be sent out by January 12th (next Monday).
- People are asked to review and add to it next week. The goal is to allow multiple people to edit simultaneously for efficiency.
- Resources can be put in an appendix and not counted towards the total page number.
- Streamlining the content is needed, with links to external resources.
- Figures and tables can replace text to facilitate understanding.
- Everyone should have a chance to review the finalized version.

- Consolidating references into one list will reduce the length.
- Claire is compiling references into a Word document titled "bibliography".
- Suggestion to use EndNote or Mendeley for easier editing.
- The bibliography should be at the end of the white paper document for constant updating.
- New versions will be created and old versions will be archived.

Commentary Update

- The commentary was submitted to Diabetes Technology of Therapeutics (DTT).
- DTT suggested submitting to Diabetes Technology and Obesity Medicine instead.
- The commentary is being reformatted to align with the new journal.
- It's being submitted as an original article because the new journal doesn't accept commentaries.
- The group received an email from DTT regarding their decision.
- Nicole or Trevon can reply to the email to inquire about the appropriate article type.

Timeline Review (January - December 2026)

- January-February 2026:
 - Submit commentary by the end of the week.
 - Group review of the white paper in the next couple of weeks.
- March-August 2026:
 - Incorporate the white paper and clinical workflows.
 - Draft a change package.
- September-December 2026:
 - Final group call.
 - Finalize the change package.
 - Share updates on white paper implementation.

White Paper Implementation and Dissemination

- The goal is for the white paper to be used as guidelines/protocols within practices, based on compiled information and FDA approval.
- Suggestion to distribute the white paper to PES or Endo Society and develop a survey to determine its usefulness.
- Share the white paper with internal staff who may not be screening as much.

JCEM Submission

- JCEM tentatively approved a submission from the group.

- Paul Stewart told Rich that JCEM is looking for reports and recommendations, typically 3,600 words in length.
- JCEM is not looking to do commentaries in the near future.
- JCEM is a better journal to submit to because the other journal doesn't have an impact factor.
- The speaker suggests looking at the original paper and seeing how it meets JCEM's guidelines.
- Index everyone on the paper if it's based on the beta cell preservation working group.

Review and Access to Shared Document

- Send a reminder email next week for the group to review the document within the next seven days.
- Dr. Broome and Rady have challenges accessing the shared document.
- Rady can access the documents on their personal computer.
- Next meeting is February 3rd, aiming for a final draft by then.

Discussion and Priorities for Next Steps

- Seeking clarity and feasibility on the white paper.
- The aim is to create a helpful tool for practices outside the collaborative.
- Share new templates, education, or learnings through the QI email for incorporation into the change package.
- Focus on experiences with stage three labeling, including barriers and facilitators.
- Update language to reflect "expected relief" regarding teplizumab approval for stage three.
- Add a section later for post-implementation after approval.
- The group will look into reformatting the paper and having the group read it next week.
- Next meeting: Tuesday February 3rd, 2026 @4pm EST

Recording:

<https://us02web.zoom.us/rec/share/ASAsjNjvJRHrn6NSHo8Bx1IGzxSa4s2qXva77wxR-7W20dKJveX0f8m9LCyDnRhV.MhJNObdVlU3DBwDj?from=hub>

Passcode: WbT0jw+S